The use of systematic reviews to justify phase III ophthalmology trials: an analysis

利用系统评价论证眼科III期临床试验的合理性:一项分析

阅读:1

Abstract

BACKGROUND/OBJECTIVE: Given the drastic increase in publication output in recent years, minimizing research waste should be a top priority. There are established areas of concern regarding research waste within ophthalmology along with a lack of systematic review usage to inform trial design in other areas of medicine. Given these concerns, the aim of this study is to evaluate the use of systematic reviews as justification for conducting randomized controlled trials (RCT) in top ophthalmology and optometry journals. METHODS: We searched PubMed on December 5, 2018 for RCTs published in one of the top five Google Scholar h-5 index journals within Ophthalmology and Optometry. We used a pilot-tested Google Form and searched each RCT for systematic reviews. Each systematic review was then given the designation of "verbatim", "inferred", or "not used as justification for conducting the RCT" based on the context the systematic review was used. RESULTS: Our analysis yielded 152 included phase III RCTs. We found 22.4% (34 of 152) of phase III ophthalmology clinical trials cited a systematic review as justification for conducting the trial. A total of 102 systematic reviews were cited in the 152 RCTs. Fifty-seven of the one hundred fifty-two (37.5%) RCTs cited a systematic review somewhere in the manuscript. CONCLUSION: Less than one-quarter of phase III RCTs cited systematic reviews as justification for conducting the RCT. We believe placing a higher priority on justifying RCTs with systematic reviews would go a long way to minimizing research waste within ophthalmology.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。